

Robert C Welsh

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/8432609/publications.pdf>

Version: 2024-02-01

216
papers

9,115
citations

66315

42
h-index

46771

89
g-index

221
all docs

221
docs citations

221
times ranked

9956
citing authors

#	ARTICLE	IF	CITATIONS
1	Primary Percutaneous Coronary Intervention and Application of the Pharmacoinvasive Approach Within ST-Elevation Myocardial Infarction Care Networks. <i>Canadian Journal of Cardiology</i> , 2022, 38, S5-S16.	0.8	2
2	Remote ischaemic conditioning in ST elevation myocardial infarction: a registry-based randomised trial. <i>Heart</i> , 2022, 108, 703-709.	1.2	2
3	Prevalence of Cardiovascular Disease in a Population-Based Cohort of High-Cost Healthcare Services Users. <i>CJC Open</i> , 2022, 4, 180-188.	0.7	2
4	Long-Term Outcomes for Patients With Acute Coronary Syndrome and Nonvalvular Atrial Fibrillation. <i>American Journal of Cardiology</i> , 2022, , .	0.7	0
5	Impact of prior oral anticoagulant use and outcomes on patients from secondary analysis in the AUGUSTUS trial. <i>Open Heart</i> , 2022, 9, e001892.	0.9	0
6	Evaluation and management of chronic kidney disease patients with stable ischemic heart disease. <i>Atherosclerosis</i> , 2022, , .	0.4	0
7	Patients selected for dual pathway inhibition in clinical practice have similar characteristics and outcomes to those included in the COMPASS randomized trial: The XATOA Registry. <i>European Heart Journal - Cardiovascular Pharmacotherapy</i> , 2022, 8, 825-836.	1.4	9
8	Multi-vessel spontaneous coronary artery dissection in a patient with aortic dissection: a case report. <i>European Heart Journal - Case Reports</i> , 2022, 6, .	0.3	2
9	Outcome and Cost of Optimal Control of Dyslipidemia in Adults With High Risk for Cardiovascular Disease. <i>Canadian Journal of Cardiology</i> , 2021, 37, 66-76.	0.8	4
10	The Healthcare Cost Burden in Adults with High Risk for Cardiovascular Disease. <i>PharmacoEconomics - Open</i> , 2021, 5, 425-435.	0.9	8
11	Long-term Clinical Outcomes Following Revascularization in High-risk Coronary Anatomy Patients With Stable Ischemic Heart Disease. <i>Journal of the American Heart Association</i> , 2021, 10, e018104.	1.6	13
12	Safety and Efficacy of Intracoronary Thrombolysis as Adjunctive Therapy to Primary PCI in STEMI: A Systematic Review and Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2021, 37, 339-346.	0.8	16
13	Lipid Testing, Lipid-Modifying Therapy, and PCSK9 (Proprotein Convertase Subtilisin-Kexin Type 9) Inhibitor Eligibility in 27,979 Patients With Incident Acute Coronary Syndrome. <i>Circulation: Cardiovascular Quality and Outcomes</i> , 2021, 14, e006646.	0.9	13
14	Temporal Trends in in-Hospital Bleeding and Transfusion in a Contemporary Canadian ST-Elevation Myocardial Infarction Patient Population. <i>CJC Open</i> , 2021, 3, 479-487.	0.7	1
15	Drug Adherence and Long-Term Outcomes in Non-Revascularized Patients Following Acute Myocardial Infarction. <i>American Journal of Cardiology</i> , 2021, 152, 49-56.	0.7	5
16	Antithrombotic Therapy After Percutaneous Coronary Intervention in Patients with Atrial Fibrillation: Findings from the CONNECT AF+PCI study. <i>CJC Open</i> , 2021, 3, 1419-1427.	0.7	1
17	Long-term risk of death and recurrent cardiovascular events following acute coronary syndromes. <i>PLoS ONE</i> , 2021, 16, e0254008.	1.1	12
18	Use of antithrombotic therapy for secondary prevention in patients with stable atherosclerotic cardiovascular disease: Insights from the COordinated National Network to Engage Cardiologists in the antithrombotic Treatment of patients with CardioVascular Disease (CONNECT-CVD) study. <i>International Journal of Clinical Practice</i> , 2021, 75, e14597.	0.8	2

#	ARTICLE	IF	CITATIONS
19	Complete Revascularization in Patients Undergoing a Pharmacoinvasive Strategy for ST-Segmentâ€“Elevation Myocardial Infarction: Insights From the COMPLETE Trial. <i>Circulation: Cardiovascular Interventions</i> , 2021, 14, e010458.	1.4	2
20	Medical Management of Peripheral Arterial Disease: Deciphering the Intricacies of Therapeutic Options. <i>CJC Open</i> , 2021, 3, 936-949.	0.7	6
21	Clinical factors associated with peripheral artery disease in patients with documented coronary artery disease: A post hoc analysis of the COMPASS trial. <i>Atherosclerosis</i> , 2021, 331, 38-44.	0.4	1
22	Ticagrelor or clopidogrel dual antiplatelet therapy following a pharmacoinvasive strategy in <sc>ST</sc>â€“segment elevation myocardial infarction. <i>Clinical Cardiology</i> , 2021, 44, 1543-1550.	0.7	4
23	Development of Acute Myocardial Infarction Mortality and Readmission Models for Public Reporting on Hospital Performance in Canada. <i>CJC Open</i> , 2021, 3, 1051-1059.	0.7	6
24	Surgical Repair of a Transannular Rupture During Transfemoral Transcatheter Aortic Valve Replacement. <i>Clinical Medicine Insights: Case Reports</i> , 2021, 14, 117954762110381.	0.3	1
25	Ambulance use, distance and outcomes in patients with suspected cardiovascular disease: a registry-based geographic information system study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2020, 9, 45-58.	0.4	14
26	A Controlled Trial of Rivaroxaban after Transcatheter Aortic-Valve Replacement. <i>New England Journal of Medicine</i> , 2020, 382, 120-129.	13.9	362
27	Applying evidence-based antiplatelet therapy in patients following a myocardial infarction without percutaneous coronary revascularization. <i>European Heart Journal</i> , 2020, 41, 1633-1635.	1.0	1
28	Inequity in Access to Transcatheter Aortic Valve Replacement: A Pan-Canadian Evaluation of Wait-Times. <i>Canadian Journal of Cardiology</i> , 2020, 36, 844-851.	0.8	18
29	Cardiac Stress Testing After Coronary Revascularization. <i>American Journal of Cardiology</i> , 2020, 136, 9-14.	0.7	7
30	Is There a Sex Gap in Surviving an Acute Coronary Syndrome or Subsequent Development of Heart Failure?. <i>Circulation</i> , 2020, 142, 2231-2239.	1.6	39
31	Very Early Changes in Quality of Life After Transcatheter Aortic Valve Replacement: Results From the 3M TAVR Trial. <i>Cardiovascular Revascularization Medicine</i> , 2020, 21, 1573-1578.	0.3	19
32	Effect of Genotype-Guided Oral P2Y12 Inhibitor Selection vs Conventional Clopidogrel Therapy on Ischemic Outcomes After Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2020, 324, 761.	3.8	257
33	Landscape of Lipid Management Following an Acute Coronary Syndrome Event: Survey of Canadian Specialists. <i>CJC Open</i> , 2020, 2, 625-631.	0.7	1
34	The Second Strategic Reperfusion Early After Myocardial Infarction (STREAM-2) study optimizing pharmacoinvasive reperfusion strategy in older ST-elevation myocardial infarction patients. <i>American Heart Journal</i> , 2020, 226, 140-146.	1.2	13
35	Effects of Transcatheter Aortic Valve Implantation on Frailty and Quality of Life. <i>CJC Open</i> , 2020, 2, 79-84.	0.7	4
36	Rivaroxaban Plus Aspirin Versus Aspirin Alone in Patients With Prior Percutaneous Coronary Intervention (COMPASS-PCI). <i>Circulation</i> , 2020, 141, 1141-1151.	1.6	39

#	ARTICLE	IF	CITATIONS
37	Long-Term Outcomes of Complete Revascularization With Percutaneous Coronary Intervention in Acute Coronary Syndromes. <i>JACC: Cardiovascular Interventions</i> , 2020, 13, 1557-1567.	1.1	20
38	Dual-pathway inhibition for secondary and tertiary antithrombotic prevention in cardiovascular disease. <i>Nature Reviews Cardiology</i> , 2020, 17, 242-257.	6.1	87
39	Update to Evidence-Based Secondary Prevention Strategies After Acute Coronary Syndrome. <i>CJC Open</i> , 2020, 2, 402-415.	0.7	6
40	Outcomes Among Clopidogrel, Prasugrel, and Ticagrelor in ST-Elevation Myocardial Infarction Patients Who Underwent Primary Percutaneous Coronary Intervention From the TOTAL Trial. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1377-1385.	0.8	24
41	Invasive and antiplatelet treatment of patients with non-ST-segment elevation myocardial infarction: Understanding and addressing the global risk-treatment paradox. <i>Clinical Cardiology</i> , 2019, 42, 1028-1040.	0.7	14
42	Outcomes Following Transcatheter Aortic Valve Replacement for Degenerative Stentless Versus Stented Bioprostheses. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 1256-1263.	1.1	46
43	Pharmacoinvasive Strategy Versus Primary Percutaneous Coronary Intervention in ST-Elevation Myocardial Infarction in Clinical Practice. <i>Circulation: Cardiovascular Interventions</i> , 2019, 12, e008059.	1.4	35
44	2019 Canadian Cardiovascular Society Position Statement for Transcatheter Aortic Valve Implantation. <i>Canadian Journal of Cardiology</i> , 2019, 35, 1437-1448.	0.8	85
45	Complete Revascularization with Multivessel PCI for Myocardial Infarction. <i>New England Journal of Medicine</i> , 2019, 381, 1411-1421.	13.9	542
46	Atrial fibrillation with percutaneous coronary intervention: Navigating the minefield of antithrombotic therapies. <i>Atherosclerosis</i> , 2019, 289, 118-125.	0.4	6
47	Canadian spontaneous coronary artery dissection cohort study: in-hospital and 30-day outcomes. <i>European Heart Journal</i> , 2019, 40, 1188-1197.	1.0	275
48	Success Begins With Failure: An Alternative Approach in Transfemoral Transcatheter Aortic Valve Replacement Using an Antegrade Wire Crossing Technique. <i>CJC Open</i> , 2019, 1, 150-152.	0.7	1
49	P2Y12 Inhibitor Switching in Response to Routine Notification of CYP2C19 Clopidogrel Metabolizer Status Following Acute Coronary Syndromes. <i>JAMA Cardiology</i> , 2019, 4, 680.	3.0	9
50	Utilization and Costs of Noninvasive Cardiac Tests After Acute Coronary Syndromes: Insights From the Alberta COAPT Study. <i>CJC Open</i> , 2019, 1, 76-83.	0.7	4
51	The Vancouver 3M (Multidisciplinary, Multimodality, But Minimalist) Clinical Pathway Facilitates Safe Next-Day Discharge Home at Low-, Medium-, and High-Volume Transfemoral Transcatheter Aortic Valve Replacement Centers. <i>JACC: Cardiovascular Interventions</i> , 2019, 12, 459-469.	1.1	179
52	2019 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Guidelines on the Acute Management of ST-Elevation Myocardial Infarction: Focused Update on Regionalization and Reperfusion. <i>Canadian Journal of Cardiology</i> , 2019, 35, 107-132.	0.8	109
53	Applying contemporary antithrombotic therapy in the secondary prevention of chronic atherosclerotic cardiovascular disease. <i>American Heart Journal</i> , 2019, 218, 100-109.	1.2	7
54	Outcomes of medically managed patients with myocardial infarction. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2019, 8, 571-581.	0.4	5

#	ARTICLE	IF	CITATIONS
55	Marital status and outcomes after myocardial infarction: Observations from the Canadian Observational Antiplatelet Study (COAPT). <i>Clinical Cardiology</i> , 2018, 41, 285-292.	0.7	7
56	Population-level incidence and outcomes of myocardial infarction with non-obstructive coronary arteries (MINOCA): Insights from the Alberta contemporary acute coronary syndrome patients invasive treatment strategies (COAPT) study. <i>International Journal of Cardiology</i> , 2018, 264, 12-17.	0.8	96
57	Kidney function modifies the selection of treatment strategies and long-term survival in stable ischaemic heart disease: insights from the Alberta Provincial Project for Outcomes Assessment in Coronary Heart Disease (APPROACH) registry. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2018, 4, 274-282.	1.8	17
58	The Healthcare Cost Burden of Acute Myocardial Infarction in Alberta, Canada. <i>PharmacoEconomics - Open</i> , 2018, 2, 433-442.	0.9	19
59	2018 Canadian Cardiovascular Society/Canadian Association of Interventional Cardiology Focused Update of the Guidelines for the Use of Antiplatelet Therapy. <i>Canadian Journal of Cardiology</i> , 2018, 34, 214-233.	0.8	181
60	Relationship between community hospital versus pre-hospital location of randomisation and clinical outcomes in ST-elevation myocardial infarction patients: insights from the Stream study. <i>European Heart Journal: Acute Cardiovascular Care</i> , 2018, 7, 504-513.	0.4	8
61	Canadian Cardiovascular Society and Canadian Institute of Health Information Public Reporting of Percutaneous Coronary Intervention Quality Indicators. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1539-1540.	0.8	1
62	Evolution of Procedural and Clinical Outcomes After Balloon-Expanding Transcatheter Aortic Valve Implantation In Canada (from the Early Canadian Experience and SOURCE XT Registries). <i>American Journal of Cardiology</i> , 2018, 122, 461-467.	0.7	1
63	Transcatheter Mitral Valve Intervention for Chronic Mitral Regurgitation: A Plethora of Different Technologies. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1200-1209.	0.8	7
64	Ethnic and sex differences in ambulance activation among hospitalized patients with acute coronary syndromes: Insights from the Alberta contemporary acute coronary syndrome patients invasive treatment strategies (COAPT) study. <i>International Journal of Cardiology</i> , 2018, 272, 33-39.	0.8	3
65	Resource Use and Burden of Hospitalization, Outpatient, Physician, and Drug Costs in Short- and Long-term Care After Acute Myocardial Infarction. <i>Canadian Journal of Cardiology</i> , 2018, 34, 1298-1306.	0.8	18
66	Trial design: Rivaroxaban for the prevention of major cardiovascular events after transcatheter aortic valve replacement: Rationale and design of the GALILEO study. <i>American Heart Journal</i> , 2017, 184, 81-87.	1.2	95
67	Challenges of Assessing Common Problems Presenting in Uncommon High-Risk Patient Populations. <i>JAMA Cardiology</i> , 2017, 2, 258.	3.0	0
68	Identifying Low-Risk Patients for Early Discharge From Emergency Department Without Using Subjective Descriptions of Chest Pain: Insights From Providing Rapid Out of Hospital Acute Cardiovascular Treatment (<scp>PROACT</scp>) 3 and 4 Trials. <i>Academic Emergency Medicine</i> , 2017, 24, 691-700.	0.8	2
69	Quality of life following coronary artery bypass graft surgery vs. percutaneous coronary intervention in diabetics with multivessel disease: a five-year registry study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2017, 3, 216-223.	1.8	6
70	Hospital variation in treatment and outcomes in acute coronary syndromes: Insights from the Alberta Contemporary Acute Coronary Syndrome Patients Invasive Treatment Strategies (COAPT) study. <i>International Journal of Cardiology</i> , 2017, 241, 70-75.	0.8	11
71	Aspirin Versus Aspirin Plus Clopidogrel as Antithrombotic Treatment Following Transcatheter Aortic Valve Replacement With a Balloon-Expandable Valve. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1357-1365.	1.1	264
72	Utility of Unfractionated Heparin in Transradial Cardiac Catheterization: A Systematic Review and Meta-analysis. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1245-1253.	0.8	9

#	ARTICLE	IF	CITATIONS
73	Clinically significant bleeding with low-dose rivaroxaban versus aspirin, in addition to P2Y12 inhibition, in acute coronary syndromes (GEMINI-ACS-1): a double-blind, multicentre, randomised trial. <i>Lancet</i> , The, 2017, 389, 1799-1808.	6.3	174
74	Structural Heart Disease Intervention: The Canadian Landscape. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1197-1200.	0.8	5
75	Temporal Trends of Reperfusion Strategies and Hospital Mortality for Patients With STEMI in Percutaneous Coronary Interventionâ€œCapable Hospitals. <i>Canadian Journal of Cardiology</i> , 2017, 33, 485-492.	0.8	12
76	Recalibrating Reperfusion Waypoints. <i>Circulation</i> , 2017, 136, 1474-1476.	1.6	2
77	Bare metal versus drug eluting stents for ST-segment elevation myocardial infarction in the TOTAL trial. <i>International Journal of Cardiology</i> , 2017, 248, 120-123.	0.8	3
78	Quality of Acute Myocardial Infarction Care in Canada: A 10-Year Review of 30-Day In-Hospital Mortality and 30-Day Hospital Readmission. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1319-1326.	0.8	20
79	Adult Congenital Heart Disease Intervention: The Canadian Landscape. <i>Canadian Journal of Cardiology</i> , 2017, 33, 1201-1205.	0.8	3
80	Thrombo-embolic prevention after transcatheter aortic valve implantation. <i>European Heart Journal</i> , 2017, 38, 3341-3350.	1.0	59
81	Reply. <i>JACC: Cardiovascular Interventions</i> , 2017, 10, 1599-1600.	1.1	2
82	Relationships Between Baseline Q Waves, Time From Symptom Onset, and Clinical Outcomes in ST-Segmentâ€œElevation Myocardial Infarction Patients. <i>Circulation: Cardiovascular Interventions</i> , 2017, 10, .	1.4	13
83	GRACE risk score: Sex-based validity of in-hospital mortality prediction in Canadian patients with acute coronary syndrome. <i>International Journal of Cardiology</i> , 2017, 244, 24-29.	0.8	19
84	Outcomes and Prognostic Impact of Prophylactic Oral Anticoagulation in Anterior STâ€œSegment Elevation Myocardial Infarction Patients With Left Ventricular Dysfunction. <i>Journal of the American Heart Association</i> , 2017, 6, .	1.6	19
85	Longitudinal treatment patterns with ADP receptor inhibitors after myocardial infarction: Insights from the Canadian Observational AntiPlatelet sTudy. <i>International Journal of Cardiology</i> , 2017, 228, 459-464.	0.8	9
86	Patient and System-Related Delays of Emergency Medical Services Use in Acute ST-Elevation Myocardial Infarction: Results from the Third Gulf Registry of Acute Coronary Events (Gulf RACE-3Ps). <i>PLoS ONE</i> , 2016, 11, e0147385.	1.1	32
87	Duration of dual antiplatelet therapy and associated outcomes following percutaneous coronary intervention for acute myocardial infarction: contemporary practice insights from the Canadian Observational Antiplatelet Study. <i>European Heart Journal Quality of Care & Clinical Outcomes</i> , 2016, 3, ocw051.	1.8	5
88	Relationship Between Arterial Access and Outcomes in STâ€œElevation Myocardial Infarction With a Pharmacoinvasive Versus Primary Percutaneous Coronary Intervention Strategy: Insights From the STRategic Reperfusion Early After Myocardial Infarction (STREAM) Study. <i>Journal of the American Heart Association</i> , 2016, 5, .	1.6	5
89	Direct oral anticoagulant use and stent thrombosis following an acute coronary syndrome: A potential new pharmacological option?. <i>Archives of Cardiovascular Diseases</i> , 2016, 109, 359-369.	0.7	1
90	Temporal and Provincial Variation in Ambulance Use Among Patients Who Present to Acute Care Hospitals With ST-Elevation Myocardial Infarction. <i>Canadian Journal of Cardiology</i> , 2016, 32, 949-955.	0.8	14

#	ARTICLE	IF	CITATIONS
91	Evaluating clinical reason and rationale for not delivering reperfusion therapy in ST elevation myocardial infarction patients: Insights from a comprehensive cohort. <i>International Journal of Cardiology</i> , 2016, 216, 99-103.	0.8	3
92	Secondary Prevention Beyond Hospital Discharge for Acute Coronary Syndrome: Evidence-Based Recommendations. <i>Canadian Journal of Cardiology</i> , 2016, 32, S15-S34.	0.8	9
93	Prognostic value of dynamic electrocardiographic T wave changes in non-ST elevation acute coronary syndrome. <i>Heart</i> , 2016, 102, 1396-1402.	1.2	13
94	Transcatheter Valve-in-Valve: A Cautionary Tale. <i>Annals of Thoracic Surgery</i> , 2016, 102, e211-e213.	0.7	5
95	Ischemic and bleeding events in patients with myocardial infarction undergoing percutaneous coronary intervention who require oral anticoagulation: Insights from the Canadian observational AntiPlatelet sTudy. <i>American Heart Journal</i> , 2016, 180, 82-89.	1.2	19
96	Baseline characteristics, adenosine diphosphate receptor inhibitor treatment patterns, and in-hospital outcomes of myocardial infarction patients undergoing percutaneous coronary intervention in the prospective Canadian Observational AntiPlatelet sTudy (COAPT). <i>American Heart Journal</i> , 2016, 181, 26-34.	1.2	16
97	A critical reappraisal of aspirin for secondary prevention in patients with ischemic heart disease. <i>American Heart Journal</i> , 2016, 181, 92-100.	1.2	20
98	Quality of Care for Percutaneous Coronary Intervention: Development of Canadian Cardiovascular Society Quality Indicators. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1570-1573.	0.8	5
99	Selecting the Duration of Antiplatelet Therapy Following Percutaneous Coronary Intervention. <i>Journal of the American College of Cardiology</i> , 2016, 68, 1865-1867.	1.2	0
100	Exploring unmet needs in venous and arterial thromboembolism with rivaroxaban. <i>Thrombosis and Haemostasis</i> , 2016, 116, S2-S12.	1.8	7
101	Defining and validating comorbidities and procedures in ICD-10 health data in ST-elevation myocardial infarction patients. <i>Medicine (United States)</i> , 2016, 95, e4554.	0.4	25
102	Alignment of site versus adjudication committee-based diagnosis with patient outcomes: Insights from the Providing Rapid Out of Hospital Acute Cardiovascular Treatment 3 trial. <i>Clinical Trials</i> , 2016, 13, 140-148.	0.7	13
103	Complete vs Culprit-Only Percutaneous Coronary Intervention in STEMI With Multivessel Disease: A Meta-analysis and Trial Sequential Analysis of Randomized Trials. <i>Canadian Journal of Cardiology</i> , 2016, 32, 1542-1551.	0.8	37
104	A randomized trial to compare the safety of rivaroxaban vs aspirin in addition to either clopidogrel or ticagrelor in acute coronary syndrome: The design of the GEMINI-ACS-1 phase II study. <i>American Heart Journal</i> , 2016, 174, 120-128.	1.2	29
105	The Demise of Morphine Oxygen Nitroglycerin Aspirin (MONA). <i>Canadian Journal of Cardiology</i> , 2016, 32, 1578.e7.	0.8	1
106	Sulfonylurea use is associated with larger infarct size in patients with diabetes and ST-elevation myocardial infarction. <i>International Journal of Cardiology</i> , 2016, 202, 126-130.	0.8	9
107	Outcomes after thrombus aspiration for ST elevation myocardial infarction: 1-year follow-up of the prospective randomised TOTAL trial. <i>Lancet, The</i> , 2016, 387, 127-135.	6.3	187
108	Bleeding in STEMI with staged multivessel PCI: is it truly benign?. <i>EuroIntervention</i> , 2016, 12, 1203-1205.	1.4	1

#	ARTICLE	IF	CITATIONS
109	Validity and utility of ICD-10 administrative health data for identifying ST- and non-ST-elevation myocardial infarction based on physician chart review. <i>CMAJ Open</i> , 2015, 3, E413-E418.	1.1	40
110	Providing Rapid Out of Hospital Acute Cardiovascular Treatment 4 (PROACT-4). <i>Journal of the American Heart Association</i> , 2015, 4, .	1.6	26
111	Dopamine receptor blockade improves pulmonary gas exchange but decreases exercise performance in healthy humans. <i>Journal of Physiology</i> , 2015, 593, 3147-3157.	1.3	11
112	Incorporating patient preferences into clinical trial design: Results of the Opinions of Patients on Treatment Implications of New Studies (OPTIONS) project. <i>American Heart Journal</i> , 2015, 169, 122-131.e22.	1.2	24
113	Cardiovascular Risk Factors and In-hospital Mortality in Acute Coronary Syndromes: Insights From the Canadian Global Registry of Acute Coronary Events. <i>Canadian Journal of Cardiology</i> , 2015, 31, 1455-1461.	0.8	37
114	Transcatheter aortic valve implantation in patients with bicuspid aortic valve: A patient level multi-center analysis. <i>International Journal of Cardiology</i> , 2015, 189, 282-288.	0.8	82
115	Randomized Trial of Primary PCI with or without Routine Manual Thrombectomy. <i>New England Journal of Medicine</i> , 2015, 372, 1389-1398.	13.9	536
116	Treatment choices in elderly patients with ST: elevation myocardial infarction—insights from the Vital Heart Response registry. <i>Open Heart</i> , 2015, 2, e000235.	0.9	39
117	Exercise training improves aerobic capacity, muscle strength, and quality of life in renal transplant recipients. <i>Applied Physiology, Nutrition and Metabolism</i> , 2014, 39, 566-571.	0.9	34
118	Inching Closer to a Solution: Sorting Out the Optimal Strategy for STEMI Patients With Multi-Vessel Coronary Artery Disease. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1501-1502.	0.8	0
119	Impact of Reperfusion Strategy on Aborted Myocardial Infarction: Insights From a Large Canadian ST-Elevation Myocardial Infarction Clinical Registry. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1570-1575.	0.8	13
120	Pharmacodynamic and Clinical Implications of Switching Between P2Y12 Receptor Antagonists. <i>Critical Pathways in Cardiology</i> , 2014, 13, 156-158.	0.2	9
121	Design and rationale of the TOTAL trial: A randomized trial of routine aspiration Thrombectomy with percutaneous coronary intervention (PCI) versus PCI Alone in patients with ST-elevation myocardial infarction undergoing primary PCI. <i>American Heart Journal</i> , 2014, 167, 315-321.e1.	1.2	66
122	Complete vs culprit-only revascularization for patients with multivessel disease undergoing primary percutaneous coronary intervention for ST-segment elevation myocardial infarction: A systematic review and meta-analysis. <i>American Heart Journal</i> , 2014, 167, 1-14.e2.	1.2	139
123	Increased Uptake of Guideline-Recommended Oral Antiplatelet Therapy: Insights from the Canadian Acute Coronary Syndrome Reflective. <i>Canadian Journal of Cardiology</i> , 2014, 30, 1725-1731.	0.8	26
124	Medial frontal cortex and anterior insula are less sensitive to outcome predictability when monetary stakes are higher. <i>Social Cognitive and Affective Neuroscience</i> , 2014, 9, 1625-1631.	1.5	3
125	Early eplerenone treatment in patients with acute ST-elevation myocardial infarction without heart failure: The Randomized Double-Blind Reminder Study. <i>European Heart Journal</i> , 2014, 35, 2295-2302.	1.0	128
126	Outcomes of a Pharmacoinvasive Strategy for Successful Versus Failed Fibrinolysis and Primary Percutaneous Intervention in Acute Myocardial Infarction (from the Strategic Reperfusion Early) Tj ETQq0 0 0 rgBT Overlock 14 Tf 50 52		

#	ARTICLE	IF	CITATIONS
127	Providing Rapid Out of Hospital Acute Cardiovascular Treatment 3 (PROACT-3). Canadian Journal of Cardiology, 2014, 30, 1208-1215.	0.8	11
128	Dopamine receptor blockade improves pulmonary gas exchange during exercise in healthy humans (717.1). FASEB Journal, 2014, 28, 717.1.	0.2	0
129	Abstract 19787: Transcatheter Aortic Valve Implantation in Patients With Bicuspid Aortic Valve: a Patient Level Multi-center Analysis. Circulation, 2014, 130, .	1.6	0
130	Treatment and Outcomes of Patients With Suspected Acute Coronary Syndromes in Relation to Initial Diagnostic Impressions (Insights from the Canadian Global Registry of Acute Coronary Events [GRACE]) Tj ETQq0 0.0,rgBT /Overlock 10 202-207.	0.7	23
131	Acute Management of ST-Elevation Myocardial Infarction Patients Taking Dabigatran. Canadian Journal of Cardiology, 2013, 29, 1531.e13-1531.e14.	0.8	3
132	Use and Timing of Coronary Angiography and Associated In-hospital Outcomes in Canadian Non-ST-Segment Elevation Myocardial Infarction Patients: Insights from the Canadian Global Registry of Acute Coronary Events. Canadian Journal of Cardiology, 2013, 29, 1429-1435.	0.8	20
133	Outcomes of Consecutive Patients Referred for Consideration for Transcatheter Aortic Valve Implantation from an Encompassing Health-Care Region. American Journal of Cardiology, 2013, 112, 1450-1454.	0.7	5
134	Bridging the Gap for Nonmetropolitan STEMI Patients Through Implementation of a Pharmacoinvasive Reperfusion Strategy. Canadian Journal of Cardiology, 2013, 29, 951-959.	0.8	15
135	Incidence of heart failure and mortality after acute coronary syndromes. American Heart Journal, 2013, 165, 379-385.e2.	1.2	80
136	Enhancing the efficacy of delivering reperfusion therapy: A European and North American experience with ST-segment elevation myocardial infarction networks. American Heart Journal, 2013, 165, 123-132.	1.2	31
137	Fibrinolysis or Primary PCI in ST-Segment Elevation Myocardial Infarction. New England Journal of Medicine, 2013, 368, 1379-1387.	13.9	595
138	Treatment and outcomes of non-ST elevation acute coronary syndromes in relation to burden of pre-existing vascular disease. International Journal of Cardiology, 2013, 168, 2720-2725.	0.8	5
139	Evaluation of early percutaneous coronary intervention vs. standard therapy after fibrinolysis for ST-segment elevation myocardial infarction: contribution of weighting the composite endpoint. European Heart Journal, 2013, 34, 903-908.	1.0	28
140	An international survey of clinical practice during primary percutaneous coronary intervention for ST-elevation myocardial infarction with a focus on aspiration thrombectomy. EuroIntervention, 2013, 8, 1143-1148.	1.4	12
141	Contemporary pharmacological reperfusion in ST elevation myocardial infarction. Current Opinion in Cardiology, 2012, 27, 340-346.	0.8	1
142	A Randomized, Double-Blind, Active-Controlled Phase 2 Trial to Evaluate a Novel Selective and Reversible Intravenous and Oral P2Y ₁₂ Inhibitor Elinogrel Versus Clopidogrel in Patients Undergoing Nonurgent Percutaneous Coronary Intervention. Circulation: Cardiovascular Interventions, 2012, 5, 336-346.	1.4	81
143	The effects of dobutamine and dopamine on intrapulmonary shunt and gas exchange in healthy humans. Journal of Applied Physiology, 2012, 113, 541-548.	1.2	40
144	Variations in practice and outcomes in patients undergoing primary percutaneous coronary intervention in the United States and Canada: Insights from the Assessment of Pexelizumab in Acute Myocardial Infarction (APEX AMI) trial. American Heart Journal, 2012, 163, 797-803.	1.2	6

#	ARTICLE	IF	CITATIONS
145	Reperfusion Strategies and Outcomes of ST-Segment Elevation Myocardial Infarction Patients in Canada: Observations From the Global Registry of Acute Coronary Events (GRACE) and the Canadian Registry of Acute Coronary Events (CANRACE). <i>Canadian Journal of Cardiology</i> , 2012, 28, 40-47.	0.8	14
146	Computer-Assisted Paramedic Electrocardiogram Interpretation With Remote Physician Over-read: The Future of Prehospital STEMI Care?. <i>Canadian Journal of Cardiology</i> , 2012, 28, 408-410.	0.8	6
147	Caring for the radial artery post-angiogram: a pilot study on a comparison of three methods of compression. <i>European Journal of Cardiovascular Nursing</i> , 2012, 11, 44-50.	0.4	5
148	Transcatheter Aortic Valve Implantation: A Canadian Cardiovascular Society Position Statement. <i>Canadian Journal of Cardiology</i> , 2012, 28, 520-528.	0.8	142
149	Pre-Dismissal Surveillance Echocardiography Second Day After TAVR. <i>JACC: Cardiovascular Imaging</i> , 2012, 5, 1182-1184.	2.3	4
150	Pharmacokinetic and Pharmacodynamic Effects of Elinogrel. <i>Circulation: Cardiovascular Interventions</i> , 2012, 5, 347-356.	1.4	33
151	Anticoagulation after subcutaneous enoxaparin is time sensitive in STEMI patients treated with tenecteplase. <i>Journal of Thrombosis and Thrombolysis</i> , 2012, 34, 126-131.	1.0	4
152	Temporal Patterns of Lipid Testing and Statin Therapy in Acute Coronary Syndrome Patients (from the Tj ETQq0 0 0 rgBT /Overlock 10 T	0.7	13
153	The Pre-Hospital Fibrinolysis Experience in Europe and North America and Implications for Wider Dissemination. <i>JACC: Cardiovascular Interventions</i> , 2011, 4, 877-883.	1.1	14
154	Temporal trends in patient and treatment delay among men and women presenting with ST-elevation myocardial infarction. <i>American Heart Journal</i> , 2011, 161, 91-97.	1.2	102
155	The influence of time from symptom onset and reperfusion strategy on 1-year survival in ST-elevation myocardial infarction: A pooled analysis of an early fibrinolytic strategy versus primary percutaneous coronary intervention from CAPTIM and WEST. <i>American Heart Journal</i> , 2011, 161, 283-290.	1.2	85
156	Has the Clopidogrel and Metoprolol in Myocardial Infarction Trial (COMMIT) of early Î²-blocker use in acute coronary syndromes impacted on clinical practice in Canada? Insights from the Global Registry of Acute Coronary Events (GRACE). <i>American Heart Journal</i> , 2011, 161, 291-297.	1.2	5
157	Refining clinical trial composite outcomes: An application to the Assessment of the Safety and Efficacy of a New Thrombolyticâ€³ (ASSENT-3) trial. <i>American Heart Journal</i> , 2011, 161, 848-854.	1.2	45
158	Mode of hospital presentation in patients with nonâ€“ST-elevation myocardial infarction: Implications for strategic management. <i>American Heart Journal</i> , 2011, 162, 436-443.	1.2	11
159	The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines. <i>Canadian Journal of Cardiology</i> , 2011, 27, S1-S59.	0.8	106
160	The Use of Antiplatelet Therapy in the Outpatient Setting: Canadian Cardiovascular Society Guidelines Executive Summary. <i>Canadian Journal of Cardiology</i> , 2011, 27, 208-221.	0.8	50
161	Determining the Cost Economic â€œTipping Pointâ€“for the Addition of a Regional Percutaneous Coronary Intervention Facility. <i>Canadian Journal of Cardiology</i> , 2011, 27, 567-572.	0.8	4
162	Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment â€“ Part 2: ST-Segment Elevation Myocardial Infarction. <i>Canadian Journal of Cardiology</i> , 2011, 27, S402-S412.	0.8	33

#	ARTICLE	IF	CITATIONS
163	Assessment and Management of Acute Coronary Syndromes (ACS): A Canadian Perspective on Current Guideline-Recommended Treatment – Part 1: Non-ST–Segment Elevation ACS. Canadian Journal of Cardiology, 2011, 27, S387-S401.	0.8	29
164	Cardiovascular Assessment of Diabetic End-Stage Renal Disease Patients Before Renal Transplantation. Transplantation, 2011, 91, 213-218.	0.5	27
165	Comparison of Impact of Mortality Risk on the Survival Benefit of Primary Percutaneous Coronary Intervention Versus Facilitated Percutaneous Coronary Intervention. American Journal of Cardiology, 2011, 107, 220-224.	0.7	2
166	Implications of variability in definition and reporting of major bleeding in randomized trials of oral P2Y12 inhibitors for acute coronary syndromes. European Heart Journal, 2011, 32, 2256-2265.	1.0	41
167	Prior Coronary Artery Bypass Graft Patients With ST-Segment Elevation Myocardial Infarction Treated With Primary Percutaneous Coronary Intervention. JACC: Cardiovascular Interventions, 2010, 3, 343-351.	1.1	69
168	Disparities in Management Patterns and Outcomes of Patients With Non–ST-Elevation Acute Coronary Syndrome With and Without a History of Cerebrovascular Disease. American Journal of Cardiology, 2010, 105, 1083-1089.	0.7	27
169	Occlusion of a Large Expanding Saphenous Vein Bypass Graft Aneurysm With Percutaneously Injected Ethylene-Vinyl Alcohol Copolymer. JACC: Cardiovascular Interventions, 2010, 3, 1089-1090.	1.1	5
170	Rear-View Mirror Observations on Bleeding in Acute Coronary Syndromes. JACC: Cardiovascular Interventions, 2010, 3, 1178-1180.	1.1	2
171	Management patterns of non-ST segment elevation acute coronary syndromes in relation to prior coronary revascularization. American Heart Journal, 2010, 159, 40-46.	1.2	24
172	Evaluation of left ventricular ejection fraction in non–ST-segment elevation acute coronary syndromes and its relationship to treatment. American Heart Journal, 2010, 159, 605-611.	1.2	11
173	Rationale and design of the randomized, double-blind trial testing INtraveNous and Oral administration of elinogrel, a selective and reversible P2Y12-receptor inhibitor, versus clopidogrel to eVALuate Tolerability and Efficacy in nonurgent Percutaneous Coronary Interventions patients (INNOVATE-PCI). American Heart Journal, 2010, 160, 65-72.	1.2	72
174	Temporal trend of in-hospital major bleeding among patients with non ST-elevation acute coronary syndromes. American Heart Journal, 2010, 160, 420-427.	1.2	22
175	Evaluation of attitudes and perceptions of key clinical stakeholders regarding out-of-hospital diagnosis and treatment of ST elevation myocardial infarction patients using a region-wide survey. Emergency Medicine Journal, 2009, 26, 371-376.	0.4	2
176	Temporal management patterns and outcomes of non-ST elevation acute coronary syndromes in patients with kidney dysfunction. European Heart Journal, 2009, 30, 549-557.	1.0	84
177	Duration of Symptoms Is the Key Modulator of the Choice of Reperfusion for ST-Elevation Myocardial Infarction. Circulation, 2009, 119, 1293-1303.	1.6	36
178	Validation of the Global Registry of Acute Coronary Event (GRACE) risk score for in-hospital mortality in patients with acute coronary syndrome in Canada. American Heart Journal, 2009, 158, 392-399.	1.2	160
179	Underutilization of clopidogrel and glycoprotein IIb/IIIa inhibitors in non–ST-elevation acute coronary syndrome patients: The Canadian Global Registry of Acute Coronary Events (GRACE) experience. American Heart Journal, 2009, 158, 917-924.	1.2	18
180	Declining In-Hospital Mortality and Increasing Heart Failure Incidence in Elderly Patients With First Myocardial Infarction. Journal of the American College of Cardiology, 2009, 53, 13-20.	1.2	309

#	ARTICLE	IF	CITATIONS
181	Canadian Cardiovascular Society Working Group: Providing a perspective on the 2007 focused update of the American College of Cardiology and American Heart Association 2004 guidelines for the management of ST elevation myocardial infarction. <i>Canadian Journal of Cardiology</i> , 2009, 25, 25-32.	0.8	31
182	Time from first medical contact to reperfusion in ST elevation myocardial infarction: A Which Early ST Elevation Myocardial Infarction Therapy (WEST) substudy. <i>Canadian Journal of Cardiology</i> , 2009, 25, 463-468.	0.8	11
183	Temporal trends in the use of invasive cardiac procedures for non-ST segment elevation acute coronary syndromes according to initial risk stratification. <i>Canadian Journal of Cardiology</i> , 2009, 25, e370-e376.	0.8	32
184	A multifaceted approach to intracoronary thrombus: Use of pharmacology, an aspiration catheter and an embolic protection device. <i>Canadian Journal of Cardiology</i> , 2009, 25, e391-e392.	0.8	1
185	Cost-effectiveness of enoxaparin compared with unfractionated heparin in ST elevation myocardial infarction patients undergoing pharmacological reperfusion: A Canadian analysis of the Enoxaparin and Thrombolysis Reperfusion for Acute Myocardial Infarction Treatment "Thrombolysis in Myocardial Infarction (ExTRACT-TIMI) 25 trial. <i>Canadian Journal of Cardiology</i> , 2009, 25, e399-e405.	0.8	6
186	Clinical in-stent restenosis with bare metal stents: Is it truly a benign phenomenon?. <i>International Journal of Cardiology</i> , 2008, 128, 378-382.	0.8	43
187	Guideline adjudicated fibrinolytic failure: Incidence, findings, and management in a contemporary clinical trial. <i>American Heart Journal</i> , 2008, 155, 121-127.	1.2	7
188	Cardiac Reserve and Pulmonary Gas Exchange Kinetics in Patients With Stroke. <i>Stroke</i> , 2008, 39, 3102-3106.	1.0	38
189	Treatment Opportunities with Fibrinolytic Therapy. <i>Fundamental and Clinical Cardiology</i> , 2008, , 71-90.	0.0	0
190	Insights into the change in brain natriuretic peptide after ST-elevation myocardial infarction (STEMI): why should it be better than baseline? This paper is one of a selection of papers published in this Special Issue, entitled Young Investigators' Forum.. <i>Canadian Journal of Physiology and Pharmacology</i> , 2007, 85, 173-178.	0.7	10
191	Pexelizumab for Acute ST-Elevation Myocardial Infarction in Patients Undergoing Primary Percutaneous Coronary Intervention. <i>JAMA - Journal of the American Medical Association</i> , 2007, 297, 43.	3.8	368
192	Clinical risk scoring beyond initial troponin values: Results from a large, prospective, unselected acute chest pain population. <i>Canadian Journal of Cardiology</i> , 2007, 23, 287-292.	0.8	4
193	A novel enoxaparin regime for ST elevation myocardial infarction patients undergoing primary percutaneous coronary intervention: A WEST sub-study. <i>Catheterization and Cardiovascular Interventions</i> , 2007, 70, 341-348.	0.7	16
194	Catheter thrombosis during primary percutaneous coronary intervention for acute ST elevation myocardial infarction despite subcutaneous low-molecular-weight heparin, acetylsalicylic acid, clopidogrel and abciximab pretreatment. <i>Canadian Journal of Cardiology</i> , 2006, 22, 511-515.	0.8	32
195	Feasibility and applicability of paramedic-based prehospital fibrinolysis in a large North American center. <i>American Heart Journal</i> , 2006, 152, 1007-1014.	1.2	50
196	Effect of acute increases in pulmonary vascular pressures on exercise pulmonary gas exchange. <i>Journal of Applied Physiology</i> , 2006, 100, 1910-1917.	1.2	34
197	Does fitness level modulate the cardiovascular hemodynamic response to exercise?. <i>Journal of Applied Physiology</i> , 2006, 100, 1895-1901.	1.2	116
198	Prolonged strenuous exercise alters the cardiovascular response to dobutamine stimulation in male athletes. <i>Journal of Physiology</i> , 2005, 569, 325-330.	1.3	50

#	ARTICLE	IF	CITATIONS
199	Coronary Artery Disease Is Common in Nonuremic, Asymptomatic Type 1 Diabetic Islet Transplant Candidates. <i>Diabetes Care</i> , 2005, 28, 866-872.	4.3	24
200	Tumour on the tricuspid valve: metastatic osteosarcoma and the heart. <i>Canadian Journal of Cardiology</i> , 2005, 21, 63-7.	0.8	9
201	Enoxaparin and percutaneous coronary intervention: a Canadian perspective. <i>Canadian Journal of Cardiology</i> , 2005, 21, 501-7.	0.8	1
202	A marriage of enhancement: fibrinolysis and conjunctive therapy. <i>Thrombosis and Haemostasis</i> , 2004, 92, 1194-1200.	1.8	14
203	Low Cardiorespiratory Fitness Is Associated With Elevated C-Reactive Protein Levels in Women With Type 2 Diabetes. <i>Diabetes Care</i> , 2004, 27, 320-325.	4.3	49
204	Intra-pulmonary shunt and pulmonary gas exchange during exercise in humans. <i>Journal of Physiology</i> , 2004, 561, 321-329.	1.3	144
205	Cardiovascular adaptations to exercise training in postmenopausal women with type 2 diabetes mellitus. <i>Cardiovascular Diabetology</i> , 2004, 3, 3.	2.7	30
206	Effects of prolonged exercise to exhaustion on left-ventricular function and pulmonary gas exchange. <i>Respiratory Physiology and Neurobiology</i> , 2004, 142, 197-209.	0.7	10
207	Variations in pre-hospital fibrinolysis process of care: insights from the Assessment of the Safety and Efficacy of a New Thrombolytic 3 Plus international acute myocardial infarction pre-hospital care survey. <i>European Journal of Emergency Medicine</i> , 2004, 11, 134-140.	0.5	20
208	Reduction of High-Sensitivity C-Reactive Protein after Treatment with Anti-Spastic Agents in Patients with Coronary Vasospastic Angina and No Hemodynamically Significant Coronary Artery Disease. <i>Chest</i> , 2004, 126, 825S.	0.4	32
209	Meta-analysis of randomized trials comparing enoxaparin versus unfractionated heparin as adjunctive therapy to fibrinolysis in ST-elevation acute myocardial infarction. <i>American Journal of Cardiology</i> , 2003, 91, 860-864.	0.7	39
210	Prehospital management of acute ST-elevation myocardial infarction: A time for reappraisal in North America. <i>American Heart Journal</i> , 2003, 145, 1-8.	1.2	88
211	Late Potentials in Female Triathletes Before and After Prolonged Strenuous Exercise. <i>Applied Physiology, Nutrition, and Metabolism</i> , 2003, 28, 153-164.	1.7	3
212	Left ventricular systolic performance during prolonged strenuous exercise in female triathletes. <i>Dynamic Medicine: DM</i> , 2003, 2, 2.	2.7	9
213	Tailoring therapy to best suit ST-segment elevation myocardial infarction: searching for the right fit. <i>Cmaj</i> , 2003, 169, 925-7.	0.9	2
214	Biochemical changes as a result of prolonged strenuous exercise. <i>British Journal of Sports Medicine</i> , 2002, 36, 301-303.	3.1	41
215	The effects of prolonged strenuous exercise on left ventricular function: A brief review. <i>Heart and Lung: Journal of Acute and Critical Care</i> , 2002, 31, 279-294.	0.8	40
216	Effects of half ironman competition on the development of late potentials. <i>Medicine and Science in Sports and Exercise</i> , 2000, 32, 1208-1213.	0.2	10